Study protocol: a hybrid effectiveness-implementation trial of Moral Reconation Therapy in the US Veterans Health Administration.
Study protocol: a hybrid effectiveness-implementation trial of Moral Reconation Therapy in the US Veterans Health Administration.
复制标题
DOI：
10.1186/s12913-018-2967-3
复制
发表时间：
2018-03-07
影响因子：
2.8
通讯作者：
Smelson D
中科院分区：
文献类型：
--
作者：
Blonigen DM;Cucciare MA;Timko C;Smith JS;Harnish A;Kemp L;Rosenthal J;Smelson D
Moral Reconation Therapy (MRT) is a cognitive-behavioral intervention aimed at reducing risk for criminal recidivism by restructuring antisocial attitudes and cognitions (i.e., “criminogenic thinking”). MRT has empirical support for reducing risk for criminal recidivism among civilian offenders. Recently, a version of MRT was developed for military veterans; however, no randomized controlled trials (RCT) have been conducted with the veteran-specific protocol, and the effectiveness and implementation potential of MRT outside of correctional settings has not been established. Using a Hybrid Type 1 RCT design, this study will test the effectiveness of MRT to reduce risk for criminal recidivism and improve health-related outcomes among justice-involved veterans entering mental health residential treatment at three US Veterans Health Administration (VHA) Medical Centers. Upon admission to the treatment program, justice-involved veterans will complete a baseline assessment, be randomized to usual care (UC) or UC + MRT, and be followed 6 and 12 months post-baseline. A process evaluation will also be conducted to identify barriers and facilitators to implementation of MRT in residential treatment. The primary aim of this study is to evaluate the effectiveness of MRT with justice-involved veterans. If MRT proves effective in this trial, the findings can provide large healthcare systems that serve veterans with an evidence-based intervention for addressing criminogenic thinking among justice-involved adults, as well as guidance on how to facilitate future implementation of MRT in non-correctional settings. This trial is funded by the VA Health Services Research & Development Program (IIR 14–081) and is registered with ClinicalTrials.gov (ID: NCT02524171).
登录
查看更多内容
影响因子：
2.3
作者：
Blue-Howells, Jessica H.;Clark, Sean C.;McGuire, James F.
通讯作者：
McGuire, James F.
影响因子：
3.1
作者：
Barkham, M;Hardy, GE;Startup, M
通讯作者：
Startup, M
影响因子：
3
作者：
Finlay, Andrea K.;Binswanger, Ingrid A.;Frayne, Susan
通讯作者：
Frayne, Susan
DOI：
10.1177/0306624x12447771
发表时间：
2013-09-01
影响因子：
1.5
作者：
Ferguson, L. Myles;Wormith, J. Stephen
通讯作者：
Wormith, J. Stephen
影响因子：
3
作者：
Curran GM;Bauer M;Mittman B;Pyne JM;Stetler C
通讯作者：
Stetler C